Previous 10 | Next 10 |
For FY20, Invitae (NVTA) reported strong growth in preliminary volume and revenue, signaling continued momentum into 2021.The company generated revenue of $278M+ (~28% Y/Y increase) with billable volume surging ~40% increase to 655K+.Year-end cash and equivalents, restricted cash and marketab...
Invitae Reports Preliminary 2020 Financial Results of More Than $278 Million in Revenue and More Than 655,000 in Billable Volume -- Presenting at the 39th Annual J.P. Morgan Healthcare Conference on January 12, 2021 at 10:50 a.m. Eastern/7:50 a.m. Pacific -- PR Newswire ...
Fulgent's core genetic testing business is recovering and should improve even further due to synergies with the COVID-19 business. Many people thought COVID-19 would dissipate in 2021 as the vaccine is rolled out, but delays in administration of the vaccine mean that testing will cont...
Invitae to Present at the 39th Annual J.P. Morgan Healthcare Conference PR Newswire SAN FRANCISCO , Dec. 29, 2020 /PRNewswire/ -- Invitae Corporation (NYSE: NVTA), a leading medical genetics company, today announced that Sean George , co-founder and c...
The rapid adoption of telemedicine and digital health during COVID-19 pandemic is remarkable, yet unsurprising. In the years preceding the health crisis we now find ourselves in, a paradigm shift in health care toward digitization was percolating. In the following piece, we explor...
The cost of sequencing a human genome has been falling faster than Moore's law. The interpretation of results is another important aspect to consider to reduce costs. Invitae is scaling up, but that also means higher R&D and SG&A expenses. However, scaling fast and doi...
Invitae Introduces Routine Exome Reanalysis to Help Patients Receive Diagnoses Faster SAN FRANCISCO , Dec. 17, 2020 /PRNewswire/ -- Invitae (NYSE: NVTA), a leading medical genetics company, today announced all patients who undergo exome testing with Invitae will rece...
Invitae to Present New Data Supporting Genetic Testing for All Breast Cancer Patients at the 2020 San Antonio Breast Cancer Symposium SAN FRANCISCO , Dec. 9, 2020 /PRNewswire/ -- Invitae (NYSE: NVTA), a leading medical genetics company, today announced three studies ...
ARKG aims to capitalize on a $9Tn TAM with the convergence of AI, DNA Sequencing and Gene-Editing. ARKG is up 149% YTD vs. the SPX return of 13%. Led by Cathie Wood, I think ARKG will be the best performing ARK Fund over the next 10 years. For further details see: ARKG: ...
Healthcare experienced a significant risk-diminishing event as the Affordable Care Act appears more secure. Biotechs continue to lead healthcare as vaccine progress and key approvals draw significant attention. Drug pricing remains a dormant issue for now although key moves last w...
News, Short Squeeze, Breakout and More Instantly...
Labcorp Announces Winning Bid for Select Assets of Invitae PR Newswire Advances Labcorp strategy to launch and scale specialty testing in areas such as oncology and rare diseases Transaction requires court approval, with confirmation expected on May 6, 2024 ...
Invitae Enters into Agreement with Labcorp for Sale of Business PR Newswire – Labcorp Selected as Winning Bidder in Court-Supervised Sale Process, Subject to Court and Regulatory Approvals – – $239 Million Cash Bid Includes Acquisition of Substantial...
Invitae Unveils New Research for Breast Cancer Patients with Variants of Uncertain Significance PR Newswire – Study findings to be presented at the 2024 American Society of Breast Surgeons Annual Meeting – SAN FRANCISCO , April 11, 2024 /PRNewsw...